Mi az ára ReNeuron Group plc (RENE)

ReNeuron Group plc (RENE) ára $0.00042815

Mi a ReNeuron Group plc (RENE piaci tőkésítése)

ReNeuron Group plc piaci tőkésítése (RENE) $13.55K

ReNeuron Group plc (RENE) Ár és Piaci Kapitalizáció

Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.

A RENE ára	B aktíva	A B piaci tőkésítése	Eredmények
$170,110 $13.55K	NVDA	$5.383T	+39,731,415,695.48%
$139,776 $13.55K	AAPL	$4.423T	+32,646,453,559.22%
$131,465 $13.55K	GOOG	$4.160T	+30,705,244,029.79%
$115,758 $13.55K	MSFT	$3.663T	+27,036,820,392.59%
$91,360.64 $13.55K	AMZN	$2.891T	+21,338,462,301.30%

A RENE ára

B aktíva

A B piaci tőkésítése

Eredmények

$170,110 $13.55K